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Cancer Genetics and Insurance
To the Editor:
Rodriguez-Bigas et al. (1998) made a commendable ef-
fort to ask 1,000 of a total of 5,178 U.S. health, dis-
ability, and life insurance companies about their policies
(and conditions) for insuring patients and asymptomatic
carriers of the gene for autosomal dominant hereditary
nonpolyposis colorectal cancer (HNPCC). The low re-
sponse rate (7.7%) and the heterogeneity of the insur-
ance companies’ attitudes (which ranged from accep-
tance to rejection of people with these types of risks) do
not warrant the authors’ optimistic conclusions that “the
majority of health, life, and disability insurance provid-
ers with an opinion would be willing to sell insurance
to both HNPCC gene carriers and at-risk individuals”
(Rodriguez-Bigas et al. 1998, p. 737). In The Nether-
lands (population 15,000,000), the health and life in-
surance companies expressed the intention to prolong a
moratorium on the use of genetic data to control access
to life insurance, at the same time that legislative efforts
were proposed to reduce the risks of genetic discrimi-
nation in access to health insurance and jobs (Committee
on Genetic Screening 1994, pp. 86–87). In industrial
countries, there is a strong tendency to reduce risk shar-
ing in health insurance and social security systems. This
tendency will cause an even greater increase in insurance
companies’ awareness of risk differentiation based on
outcomes of genetic tests (Pokorski 1995; Bodmer
1996).
In view of these nearly global developments, appro-
priate counseling on the social effects of taking a pre-
symptomatic test for a late-onset genetic disease, such
as a cancer syndrome or a neurodegenerative disorder,
has become a very delicate matter for clinical geneticists
(The Ad Hoc Committee on Genetic Testing/Insurance
Issues 1995). The silence of the majority of the insurance
companies in the U.S. study by Rodriguez-Bigas et al.
(1998) reflects the general neglect of this subject in dis-
cussions between the governments of the major eco-
nomic countries and the regulators of the international
insurance and underwriters system.
Families with these genetic risks may become bur-
dened by the unacceptable financial risks of the “wait
and see” attitude of the health and life insurance system
and the policy makers responsible for these regulations.
In Great Britain, life insurers recently started demanding
genetic-test results (Wilkie 1998).
Geneticists usually are held responsible for potential
adverse socioeconomic effects of genetic testing, by mak-
ing already foreseeable genetic risks more precise. How-
ever, from the onset of presymptomatic testing, society
and policy makers have been informed, by the genetics
community, of the need to formulate regulations based
on fairness and the prevention of genetic discrimination
(The Ad Hoc Committee on Genetic Testing/Insurance
Issues 1995).
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